Dipalmitoylphosphatidylcholine Lipid Vesicles for Delivering HMB, NMN, and L-Leucine in Sarcopenia Therapy
Molecules · 2025
DOI: 10.3390/molecules30071437 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2025. Verfasst von Alfred Najm und 9 weiteren Autor:innen. Beteiligte Einrichtung: Carol Davila University of Medicine and Pharmacy, 8 Eroii Sanitari, Sector 5, 050474 Bucharest, Romania. Hauptthemen laut MEDLINE: Sarcopenia, Leucine, 1,2-Dipalmitoylphosphatidylcholine. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Sarcopenia, characterized by the degeneration of skeletal muscle tissue, has emerged as a significant concern in recent years. This increased awareness stems from advances in research focusing on elderly patients, which have revealed correlations between aging mechanisms and muscle degeneration, beyond the mere fact that tissues age and deteriorate over time. Consequently, the present study aims to address sarcopenia by developing and evaluating DPPC lipid vesicles that encapsulate three distinct drugs: HMB, NMN, and L-Leucine. These drugs are specifically selected for their properties, which facilitate effective interaction with the affected muscle tissue, thereby promoting desired therapeutic effects. Preliminary physicochemical analyses indicate the successful formation of spherical lipid vesicles, characterized by nanometric dimensions and stable membrane integrity. The biological investigations aimed to highlight the potential of DPPC lipid vesicles encapsulating HMB, NMN, and L-Leucine to alleviate sarcopenia-induced cytotoxicity and oxidative stress. Through a comparative evaluation of the three drug formulations, we demonstrate that drug-loaded DPPC vesicles effectively mitigate oxidative damage, preserve mitochondrial function, and maintain cytoskeletal integrity in H2O2-induced C2C12 myotubes, with HMB-loaded vesicles showing the strongest protective effects against muscle degeneration. These findings underscore the therapeutic potential of DPPC-based controlled release systems for sarcopenia treatment and highlight the need for further investigations into their mechanistic role in muscle preservation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Carol Davila University of Medicine and Pharmacy, 8 Eroii Sanitari, Sector 5, 050474 Bucharest, Romania.
- Emergency Hospital Floreasca Bucharest, 8 Calea Floreasca, Sector 1, 014461 Bucharest, Romania.
- National University of Science and Technology Politehnica Bucharest, 011061 Bucharest, Romania.
- Research Institute of the University of Bucharest-ICUB, University of Bucharest, 050657 Bucharest, Romania.
- Faculty of Biology, University of Bucharest, 050657 Bucharest, Romania.
ORCID-Profile: Alfred Najm, Adelina-Gabriela Niculescu, Alexandru Mihai Grumezescu, Bianca Gălățeanu, Bogdan Ștefan Vasile, Bogdan Severus Gaspar, Ariana Hudiță
Zitieren
APA
Najm, A., Bîrcă, A. C., Niculescu, A. G., Alberts, A., Grumezescu, A. M., Gălățeanu, B., Vasile, B. Ș., Beuran, M., Gaspar, B. S., & Hudiță, A. (2025). Dipalmitoylphosphatidylcholine Lipid Vesicles for Delivering HMB, NMN, and L-Leucine in Sarcopenia Therapy. Molecules. https://doi.org/10.3390/molecules30071437
Vancouver
Najm A, Bîrcă AC, Niculescu AG, Alberts A, Grumezescu AM, Gălățeanu B, et al. Dipalmitoylphosphatidylcholine Lipid Vesicles for Delivering HMB, NMN, and L-Leucine in Sarcopenia Therapy. Molecules. 2025. doi:10.3390/molecules30071437
BibTeX
@article{Najm2025,
author = {Najm, Alfred and Bîrcă, Alexandra Cătălina and Niculescu, Adelina-Gabriela and Alberts, Adina and Grumezescu, Alexandru Mihai and Gălățeanu, Bianca and Vasile, Bogdan Ștefan and Beuran, Mircea and Gaspar, Bogdan Severus and Hudiță, Ariana},
title = {Dipalmitoylphosphatidylcholine Lipid Vesicles for Delivering HMB, NMN, and L-Leucine in Sarcopenia Therapy},
journal = {Molecules},
year = {2025},
doi = {10.3390/molecules30071437}
}
EUVIMED